1997
Antecedents of Cerebral Palsy in a Multicenter Trial of Indomethacin for Intraventricular Hemorrhage-Reply
Allan W, Vohr B, Makuch R, Katz K, Ment L. Antecedents of Cerebral Palsy in a Multicenter Trial of Indomethacin for Intraventricular Hemorrhage-Reply. JAMA Pediatrics 1997, 151: 1270-1270. DOI: 10.1001/archpedi.1997.02170490095024.Peer-Reviewed Original Research
1991
High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Research
1985
Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate
Trigg M, Makuch R, Glaubiger D. Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. International Journal Of Radiation Oncology • Biology • Physics 1985, 11: 699-702. PMID: 3838542, DOI: 10.1016/0360-3016(85)90300-1.Peer-Reviewed Original ResearchConceptsEwing's sarcomaIntrathecal methotrexateCNS irradiationProphylactic cranial irradiationGroup of patientsCurrent treatment regimensLack of efficacyNational Cancer InstituteCranial irradiationInitial therapyCNS involvementCNS recurrenceTreatment regimensCNS treatmentIrradiation regimenCancer InstituteActuarial riskSarcomaOverall riskPatientsTherapyMethotrexateRiskCNSInvolvement
1980
Influence of Histologic Subtype of Small Cell Carcinoma of the Lung on Clinical Presentation, Response to Therapy, and Survival2
Carney D, Matthews M, Ihde D, Bunn P, Cohen M, Makuch R, Gazdar A, Minna J. Influence of Histologic Subtype of Small Cell Carcinoma of the Lung on Clinical Presentation, Response to Therapy, and Survival2. Journal Of The National Cancer Institute 1980, 65: 1225-1230. PMID: 6253711, DOI: 10.1093/jnci/65.6.1225.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaHistologic subtypeCell carcinomaSame patientBiopsy tissueAggressive cytotoxic therapyChemotherapeutic response rateExtent of diseaseInitial performance statusIntermediate cell subtypeSignificant differencesPerformance statusCombination chemotherapyClinical presentationCytotoxic therapyTherapeutic decisionsPatientsLung cancer classificationResponse rateCell subtypesSubtypesTherapyCarcinomaLungWorking PartySmoking abstinence and small cell lung cancer survival. An association.
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980, 244: 2175-9. PMID: 6252357, DOI: 10.1001/jama.244.19.2175.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalTherapy
1979
Improvements in circulating levels of immune-reactive proteins simultaneous with depression of thymus-dependent lymphocytes during radiation therapy for solid malignancies
Baskies A, Chretien P, Weiss J, Makuch R, Spiegel H. Improvements in circulating levels of immune-reactive proteins simultaneous with depression of thymus-dependent lymphocytes during radiation therapy for solid malignancies. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 67-68. DOI: 10.1016/0360-3016(79)91047-2.Peer-Reviewed Original Researchcis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Young R, Von Hoff D, Gormley P, Makuch R, Cassidy J, Howser D, Bull J. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Journal Of The National Cancer Institute 1979, 63: 1539-44. PMID: 387224.Peer-Reviewed Original ResearchConceptsCombination chemotherapy studiesAdvanced ovarian cancerSingle-agent activityOverall response rateLife-table analysisOvarian Cancer StudyEvaluable patientsForced diuresisSubstantial nauseaHematologic toxicityChemotherapy studiesRenal toxicityOvarian adenocarcinomaOvarian cancerResponse ratePatientsCancer studiesTreatmentToxicityNauseaVomitingDiuresisAdenocarcinomaMajor roleTherapy